Stem cell advocates eye RFK Jr. to legitimize treatments via MAHA path

Advocates for stem cell therapies are drawing parallels to the FDA's acceptance of peptides, which gained legitimacy after being embraced by the MAHA movement. They hope RFK Jr.'s influence could similarly legitimize stem cell treatments. The outcome is uncertain, but this signals a potential shift in U.S. regulatory posture toward unproven regenerative therapies.